The high-risk HPV E6 proteins have been shown to direct the degradation of a variety of cellular proteins that contain PDZ domains. Although some of these proteins are involved in regulating processes of cell growth and polarity in Drosophila, little is known about their function in higher eukaryotic epithelial cells. In HPV-containing cells derived from cervical tumours, we find that the patterns of expression of the E6 targets hDlg (discs large), hScrib (Scribble), and MUPP1 are consistent with their being substrates for E6-induced degradation. It is also clear that, in the case of hDlg, E6 is specifically targeting nuclear pools of the protein rather than membrane-bound forms. We have also analysed the activity of a subset of E6 target proteins in the suppression of oncogene-induced cell transformation. Interestingly, Dlg, MAGI-1 and MUPP1 efficiently suppressed cell transformation, while MAGI-2 and MAGI-3 were ineffective in this assay. These results suggest that in the context of HPV-induced transformation Dlg, MAGI-1 and MUPP1 can function as tumour suppressors.
Introduction
Human papillomaviruses (HPVs) can be classified as high or low risk depending on their association with the development of human tumours. Perhaps the most important of these are those associated with the development of cervical cancer, of which HPV-16 and HPV-18 are the most common (zur Hausen, 1996) . Both viruses encode two major transforming proteins, E6 and E7 Mu¨nger et al., 2001 for reviews), the continued expression of which is required for the continued proliferation of tumour-derived cell lines (von Knebel Doeberitz et al., 1992; Alvarez-Salas et al., 1998; Butz et al., 2000) . A great deal of emphasis has been placed on defining the mechanism of action of these two viral proteins and, in particular, in identifying the cellular target proteins with which they interact. In many cases however, these proteins are also targeted by the E6 and E7 proteins of the low-risk HPV types, which are not normally associated with the development of cervical cancer. The PDZ domain-containing substrates are one of the exceptions, being targeted only by the high-risk, mucosally derived, HPV E6 proteins.
To date, six different PDZ domain-containing proteins have been shown to be susceptible to degradation by the high-risk HPV-16 and HPV-18 E6 proteins. These include discs large (Dlg) (Gardiol et al., 1999) , MAGI-1, MAGI-2 and MAGI-3 Thomas et al., 2002) , MUPP1 and Scribble (hScrib) (Nakagawa and Huibregtse, 2000) . These proteins are all characterized by having multiple protein-protein interaction motifs and are frequently expressed at sites of cell-cell contact. They are believed to function largely by regulating the formation of multicomponent protein complexes at these sites via their PDZ domains (reviewed in Kim, 1997) . The PDZ domains themselves are stretches of 80-90 amino acids in length, and these are bound by the four amino acids at the extreme carboxy-terminus of their interacting proteins (Songyang et al., 1997) . In the case of E6, this is represented by the sequence XTXV/L of HPV-18 and HPV-16 E6, respectively (Kiyono et al., 1997; Lee et al., 1997) . Through this sequence, the E6 protein can bind a single PDZ domain on each target protein, and then direct its degradation via the 26S proteasome (reviewed in Banks et al., 2003) . Of these PDZ domain-containing substrates of E6, most information is available concerning the mechanism of action of Dlg and Scrib. Based on studies in Drosophila, these proteins have been shown to act in concert to regulate the processes of cell growth and cell attachment (Woods et al., 1996; Bilder and Perrimon, 2000; Bilder et al., 2000) . In higher eukaryotic cells less is known about their function, although Dlg has been reported to induce growth arrest in mouse fibroblasts (Ishidate et al., 2000) and a Dlg truncation mutant results in impaired morphogenesis and perinatal death during murine development (Caruana and Bernstein, 2001) . Dlg is also frequently expressed at very low levels in highly transformed cells Watson et al., 2002) , suggesting that it may possess tumour suppressor activity. Much less is known about the activity of the other PDZ domain-containing substrates of E6. MAGI-1 has been shown to interact with b-catenin (Dobrosotkaya and James, 2000), while MAGI-2 and MAGI-3 have been shown to be involved in the downregulation of PKB activity through an interaction with the PTEN tumour suppressor (Wu et al., 2000a, b) . These findings suggest that all three MAGI family members may be involved in the regulation of cell proliferation. In the case of MUPP1, a large multi-PDZ domain-containing scaffolding protein with a putative role in signal transduction (Becamel et al., 2001) , there is, as yet, no clear information on its potential biological activities.
To determine which of these E6 target proteins have a role in HPV-induced cell transformation, we have analysed the patterns of protein expression in cells derived from cervical tumours, as well as assessing the activity of these proteins in the suppression of cell transformation. We show a pattern of hScrib expression that is very similar to that seen with Dlg, suggesting that this protein is also being subjected to proteasomemediated degradation in HPV-containing cells. In addition, Dlg, MUPP1 and MAGI-1 all exert a strong inhibition of cell transformation, suggesting that these E6 target proteins are potential tumour suppressors in higher eukaryotic cells.
Results

Proteasome regulation of hDlg, hScrib and MUPP1
Previous studies have shown that Dlg, hScrib and MUPP1 are subject to E6-induced proteasome-mediated degradation (Gardiol et al., 1999; Lee et al., 2000; Nakagawa and Huibregtse, 2000) . In addition, in cells derived from cervical tumours, endogenous Dlg is also subjected to proteasome-mediated regulation and the levels of expression are particularly low in cells with a highly transformed phenotype Watson et al., 2002) . We were therefore interested in analysing the status of the other PDZ domain-containing substrates of E6 in cells derived from cervical tumours.
In order to do this, we investigated the patterns of expression of hDlg, hScrib and MUPP1. Since many of these proteins are involved in large multiprotein complexes, we also investigated whether there were different pools of these proteins that were being differentially regulated. Therefore, we also analysed both the soluble and insoluble protein fractions from the different cells. The cell lines used were the HPVpositive cervical tumour-derived, CasKi, SiHa and HeLa, the HPV-negative cervical tumour-derived C33-I and HPV-negative immortalized skin keratinocytes HaCaT. To determine whether these potential E6 target proteins were being subjected to ubiquitin-mediated degradation at the 26S proteasome, extracts were also obtained from cells pretreated for 3 h with the proteasome inhibitor CBZ. The results of the Western blots are shown in Figure 1 (soluble fractions) and Figure 2 (insoluble fractions). As can be seen, hDlg is subject to proteasome-mediated degradation in all the HPV-containing cell lines, consistent with its being a substrate for E6-induced degradation in vivo. In the case of CasKi and SiHa cells, this would appear to be predominantly a soluble form of the protein, while in HeLa cells, it appears to be mostly the insoluble form. In contrast, the C33-I cells express very low levels of hDlg that are not subject to proteasome-mediated regulation, which we have shown previously to be a result of low levels of transcription . As can also be seen, the HPV-negative HaCaT cells express very high levels of hDlg that are subject to a low level of proteasome regulation. Likewise, hScrib exhibits a very similar pattern of expression, with clear regulation by the proteasome in the HPV-containing cells, but not in the HPV-negative cells. Interestingly, the bulk of the regulation also appears to be on the soluble pool of the hScrib protein. Once again these data are very consistent with hScrib being a substrate for E6-induced degradation in vivo. In the case of MUPP1, the pattern is not so clearcut, with only modest proteasome degradation occurring in CasKi and HaCaT cells. Therefore, based on these studies it is still unclear whether MUPP1 is a target of E6 in vivo. From the above analysis, it is clear that hDlg and hScrib are regulated by the proteasome in HPV-containing cells and that different pools of the proteins are being differentially affected. Therefore, we were interested in investigating further whether this represents particular pools of the proteins within distinct cellular compartments. Since hDlg has been reported to be present in different cellular compartments (McLaughlin et al., 2002) , we therefore performed immunofluorescence analysis on hDlg in the HPV-positive CasKi, SiHa and HeLa cells and the HPV-negative HaCaT cells. This was carried out in the presence and absence of proteasome inhibitors and the results obtained are shown in Figure 3 . It is clear that in all the cell lines, hDlg can be detected either at the cell periphery and at sites of cell-cell contact (CasKi and HaCaT) or within weakly staining nuclear sites (SiHa and HeLa), in agreement with previous studies (Reuver and Garner, 1998; McLaughlin et al., 2002) . However, upon treatment with proteasome inhibitors there is a marked difference between the different cell lines. In HaCaT cells, there is some degree of proteasome protection of hDlg, and this is largely the membrane-bound form of the protein. In contrast, in the HPV-positive cells, there is a very strong increase in the levels of hDlg in the nuclear regions of the cell. These results suggest that the forms of hDlg that are specifically targeted by E6 in HPV-containing cells are present within the nucleus and the cytoplasm, while the membranebound forms of hDlg are largely unaffected by E6.
In order to verify that these nuclear/cytoplasmic forms of hDlg are being specifically targeted by HPV E6, we proceeded to perform siRNA inhibition of E6/7 expression, using a recently described functional siRNA against HPV (Yoshinouchi et al., 2003) . SiHa cells were transfected with HPV siRNA or Luciferase siRNA as a control. After 72 h, the cells were fixed and stained and immunofluorescence analysis was performed for p53 and hDlg. At the same time, RT-PCR was performed to monitor HPV early gene expression and b-actin as a control. The results obtained are shown in Figure 4 . As can be seen, HPV siRNA greatly reduces the level of HPV gene expression ( Figure 4a ) and this is in agreement with previous studies (Yoshinouchi et al., 2003) . This reduction in HPV gene expression is also accompanied by a marked increase in the level of nuclear p53 (Figure 4b ), again consistent with its being rescued from E6-induced degradation. Most interestingly, however, there is a dramatic increase in the levels of nuclear and cytoplasmic hDlg expression, following siRNA inhibition of HPV gene expression (Figure 4c ). This pattern of staining is very similar to that observed following proteasome protection (Figure 3) , thereby further demonstrating that HPV E6 targets specific subcellular pools of hDlg for proteasome-mediated degradation. To investigate further the biological activities of the different PDZ domain-containing substrates of E6, we analysed their abilities to suppress cell transformation. For this assay, we used combinations of either HPV-16 E7 and EJ-ras or adenovirus E1A and EJ-ras to induce the transformation of primary baby rat kidney (BRK) cells. Cells were cotransfected with the respective oncogene pairs together with expression plasmids encoding the full-length forms of the E6-PDZ domaincontaining substrate proteins: Dlg, MAGI-1, MAGI-2, MAGI-3 and MUPP1. After 2 weeks of selection, the dishes were fixed and stained and the numbers of colonies counted. The results from a series of assays are shown in Figure 5 . As can be seen, Dlg, MAGI-1 and MUPP1 are strong inhibitors of cell transformation, regardless of whether it is induced by HPV E7/ras (Figure 5a ) or adenovirus E1A/ras (Figure 5b ). In contrast, neither MAGI-2 nor MAGI-3 has any effect on the ability of either E7/ras or E1A/ras to induce transformation of primary BRK cells. Indeed, while cell lines stably expressing MAGI-2 and MAGI-3 were generated in the course of these studies, no equivalent cell lines expressing Dlg, MAGI-1 or MUPP1 were obtained (data not shown). These results demonstrate that the E6 substrates hDlg, MAGI-1 and MUPP1 can all function as tumour suppressor proteins in the context of virus-induced transformation.
In order to investigate whether E6 could overcome the growth suppressive activity of Dlg, the transformation assay was repeated but in the presence of HPV-18 and HPV-11 E6. The results obtained are shown in Figure 5c , where it can be seen that Dlg is again a potent inhibitor of HPV-16 E7 and EJ-ras cooperation. However, addition of HPV-18 E6 efficiently overcomes this activity of Dlg, consistent with its being a substrate for E6-induced degradation. In contrast, the low risk HPV-11 E6, which cannot bind Dlg (Gardiol et al., 1999) , fails to overcome Dlg-induced suppression of transformation.
Finally, we considered it to be formally possible that the growth suppressive activity of Dlg might be due simply to a general inhibition of cell proliferation, as a consequence of the high levels of expression. In order to investigate this further, primary BRK cells were transfected with a b-gal-expressing plasmid in the presence and absence of Dlg. The cells were then stained for b-gal and the number of blue cells counted over a 96 h time course. The results obtained are shown in Figure 5d , where it can be seen that over this time period the presence of Dlg has no significant effect on the ability of the primary cells to proliferate. This suggests that the growth suppressive activity of Dlg observed in the transformation assays is not a general phenomenon due to overexpression.
Discussion
One of the unique features of the E6 proteins derived from mucosal high-risk HPV types is their ability to interact with a class of PDZ domain-containing substrates. These substrates have been implicated in the control of cell proliferation, cell polarity and cell attachment, and this set of interactions offers one explanation for the ability of E6 to contribute to HPVinduced malignancy. Indeed, loss of Dlg and hScrib expression in Drosophila results in disorganized cell growth characterized by a loss of cell polarity and proliferation control (Woods et al., 1996; Bilder and Perrimon, 2000; Bilder et al., 2000) . Until now, however, very little was known about the levels of expression of the PDZ domain-containing substrates of E6 in vivo or their respective abilities to modulate cell growth in higher eukaryotic cells. We now show that hDlg and hScrib exhibit patterns of expression consistent with their being substrates for E6-induced degradation in HPV-containing cervical tumour-derived cell lines. In addition, the E6 substrates, hDlg, MUPP1 and MAGI-1, are all potent inhibitors of virus-induced cell transformation, supporting a role for these proteins in the regulation of cell proliferation in higher eukaryotic cells.
Although hDlg, hScrib and MUPP1 have all been shown to be excellent targets for E6-induced degradation in vitro and in transient transfection experiments (Gardiol et al., 1999; Lee et al., 2000; Nakagawa and Huibregtse, 2000) , very little was known about the levels of expression of these proteins in HPV-containing cervical tumour-derived cell lines. Since many of these proteins are involved in the regulation of multicomponent protein complexes, we also reasoned that different pools of the proteins within the cell might be subject to different degrees of regulation by E6. Indeed, this would seem to be the case. Thus hDlg and hScrib both show patterns of expression and proteasome regulation that are consistent with their being substrates for E6-induced degradation in cervical tumour-derived cell lines. Most interestingly however, it would appear that E6 preferentially targets a specific form of these proteins, which in the case of hScrib and hDlg is mostly the soluble form of the protein, although some insoluble forms would also appear to be susceptible to E6-induced degradation to a lesser degree. It is tempting to speculate that, at least in the case of hDlg, the forms of the protein that are unaffected by E6 are those found within multiprotein complexes at the sites of cell-cell contact, while the form of hDlg that is degraded in HPV-positive cells represents the soluble forms of the protein (see below).
It is also worth noting that in the case of HeLa cells a significant amount of hDlg was also rescued in the insoluble fraction. Whether this reflects a difference in the activities of the HPV-16 and HPV-18 E6 proteins remains to be determined, but previous studies would suggest that this is a possibility due to the different efficiencies with which the two viral proteins can target their PDZ domain-containing substrates (Thomas et al., 2001) .
We extended this analysis to investigate whether E6 specifically targets a subset of the hDlg protein by performing immunofluorescence on cells in the presence and absence of proteasome inhibitors. Strikingly, in HPV-containing cells both the nuclear and cytoplasmic forms of hDlg appear to be targeted by E6. This result was also further verified by using siRNA ablation of HPV gene expression, where again the nuclear and cytoplasmic pools of hDlg appeared to be specifically rescued from E6-induced degradation. These results have a number of important implications. A major question concerning HPV E6 function is how it exerts a level of specificity with respect to its substrate proteins; this study shows that only a subset of the hDlg needs to be targeted by the E6 protein. This also raises the intriguing question of why E6 is targeting these particular pools. In the case of Dlg, previous studies have shown that it can be found in the nucleus (McLaughlin et al., 2002) and that it also shares many features in common with b-catenin (Matsumine et al., 1996; Reuver and Garner, 1998) . It is therefore tempting to speculate that these forms of hDlg are actually involved in signalling. This is an aspect that obviously requires further analysis, and it will now also be important to extend this analysis to the other E6 substrate proteins once suitable reagents are available.
It still remains to be determined precisely how E6 targets hDlg for degradation, since several studies have shown that hDlg is regulated by the proteasome in both E6-dependent and -independent pathways Gardiol et al., 2002; Mantovani and Banks, 2003) . It seems unlikely that E6 is augmenting the normal pathway of regulation since, in the absence of E6, the majority of hDlg that is proteasome regulated seems to be at the sites of cell-cell contact, and we have shown that E6 has minimal effects on this pool. In addition, there are also very low levels of nuclear/ cytoplasmic forms of hDlg in HPV-negative HaCaT cells, regardless of the presence or absence of proteasome inhibitors. One can speculate that hDlg is only directed to the nucleus as a negative regulator of cell growth, and this is the form targeted by E6. If this signal is lacking in HaCaT cells, either due to the absence of other HPV gene products or other signalling molecules, then we would not expect to see significant levels of nuclear forms of hDlg. Obviously, further studies are required to clarify these aspects.
Having defined which E6 substrates are subjected to degradation in HPV-containing cervical tumour-derived cell lines, we wanted to investigate which of these proteins had the potential to suppress cell transformation. Although previous studies had suggested that Dlg could suppress the growth of mouse fibroblasts (Ishidate et al., 2000) , there was no information on its ability to suppress the oncogenic transformation of primary epithelial cells. We made use of the ability of the adenovirus E1A protein and the HPV-16 E7 protein to cooperate with EJ-ras in the transformation of primary BRK cells to analyse the effects of Dlg, the MAGI family of proteins and MUPP1 upon the levels of transforming activity. Interestingly, both oncogene combinations were equally susceptible to potent suppression of transformation by Dlg, MAGI-1 and MUPP1, but were unaffected by MAGI-2 and MAGI-3. These results demonstrate that, in the context of virally induced cell transformation, Dlg, MAGI-1 and MUPP1 can act as potent inhibitors of cell transformation and this suggests that it is this activity that is targeted by the high-risk HPV E6 oncoprotein. Interestingly, this hypothesis is further supported by the recent observation that E6 requires an intact PDZbinding motif in order to induce epithelial hyperplasia in transgenic mice (Nguyen et al., 2003) .
In summary, we have determined that distinct cellular pools of hDlg and hScrib are targeted by HPV E6 for proteasome-mediated degradation, and we provide strong evidence that at least three of HPV E6's PDZ domaincontaining substrates, Dlg, MAGI-1 and MUPP1, have potent tumour suppressor activities.
Materials and methods
Cells and tissue culture
The cells lines used in this study were the HPV-16-positive CasKi and SiHA, the HPV-18-positive HeLa and the HPVnegative C3-I, all of which are derived from cervical tumours. The spontaneously immortalized HPV-negative skin keratinocyte cell line HaCaT was also used. BRK cells were obtained from 9-day-old Wistar rats and transfected using standard calcium phosphate precipitation with combinations of either HPV-16 E7 and EJ-ras or adenovirus E1a and EJ-ras, together with expression plasmids encoding Dlg, MUPP1, MAGI-1, MAGI-2 and MAGI-3. Where E6 expression plasmids were included, then pCDNA.11E6, pCDNA.16E6 and pCDNA.18E6 were used. Following 2 weeks selection in 200 mg/ml G418, the dishes were fixed and stained and the colonies counted. Cell proliferation assays were performed as described previously (Thomas et al., 1999) . Briefly, primary BRK cells were transfected with a b-gal expression plasmid together with either empty plasmid or a Dlg expression plasmid. Cells were fixed and stained at 24 h intervals and the number of blue cells counted by counting 10 random microscope fields per dish. All cells were grown in DMEM supplemented with 10% foetal calf serum.
Western blotting
The levels of expression of the different PDZ domaincontaining substrates of E6 were determined by Western blotting. Cells were grown to 50% confluency on 90 mm dishes and extracted in 250 mM NaCl, 0.1% NP40, 50 mM HEPES, pH 7.0 and 1% aprotinin, and clarified by centrifugation at 14 000 r.p.m. for 2 min. The residual supernatant represents the soluble protein fraction, while the pelleted material represents the insoluble protein fraction. The protein concentration was determined using the BioRad protein assay and equal amounts of protein were then subjected to SDS-PAGE and western blotting. For Dlg detection the blots were probed with a combination of the two monoclonal antibodies 2D11 (Santa Cruz) and Clone 12 (BD Transduction Laboratories). For Scribble detection, the goat polyclonal antibody C-20 was used (Santa Cruz), while MUPP1 was detected using a sheep polyclonal antibody (Upstate Biotechnology). Westerns were then developed using appropriate biotin-tagged secondary antibodies (DAKO) followed by avidin peroxidase (DAKO) and ECL detection (Amersham).
For proteasome inhibitor assays, the cells were treated with either 50 mM N-CBZ-Leu-Leu-Leu-AL (CBZ) proteasome inhibitor (Sigma) in DMSO or an equal amount of DMSO alone as a control 3 h prior to protein extraction.
Immunofluorescence
HaCaT, CasKi, SiHa and HeLa cells were first treated with either 50 mM CBZ or DMSO for 3 h and then washed with PBS and fixed in PBS/3.7% paraformaldehyde for 20 min. After further washing in PBS, the cells were permeabilized in PBS/ 0.1% Triton for 5 min and then washed extensively with PBS. Endogenous hDlg was visualized using an anti-hDlg monoclonal antibody 2D11 (Santa Cruz) and p53 was visualized using the anti-p53 monoclonal antibody DO-1 (Santa Cruz) followed by a secondary fluorescein-conjugated goat antimouse antibody (Molecular Probes). After extensive washing in PBS, the coverslips were mounted on slides using Vectashield mounting medium (Vector Laboratories Inc.). Images were analysed by confocal laser scanning microscopy with a Zeiss Axiovert 100M microscope attached to a LSM 510 confocal unit.
siRNA and transfections
The siRNA chosen against HPV-16 E6 mRNA has been described previously (Yoshinouchi et al., 2003) and is as follows: sense strand, 5 0 GAAUGUGUGUACUGCAAGCdTdT; antisense strand, 5 0 GCUUGCAGUACACACAUUCdTdT. siRNA against luciferase was used as a negative control. All siRNAs were synthesized and purified by Dharmacon.
SiHa cells were plated into six-well dishes at a concentration of 1 Â 10 5 per well on coverslips. Cells were transfected by combining 6 ml of Oligofectamine (Life Technologies) with 24 ml of Opti-MEM I Medium (Life Technologies). This was then added to 100 ml of Opti-MEM containing 6 ml of siRNA (20 mM). After 20 min at room temperature, the mixture was then added to the cells in 1 ml Opti-MEM. After 4 h at 371C, the medium was replaced with DMEM containing 10% FBS and the cells were analysed after 72 h.
RT-PCR
Following siRNA treatment, total cellular RNA was extracted using TRI Reagent (Sigma) according to the manufacturer's instructions. RNA (1 mg) was reverse transcribed using RETROscript (Ambion). HPV E7 and b-actin sequences were then amplified by PCR through 20 cycles. Primer pairs are as follows: E7, 5 0 GCTAGCATGCATGGAGATACACCTAC3 0 and 5 0 TCTAGATTATGGTTTCTGAGAACAGA3 0 ; b-actin, 5 0 CTCACCATGGATGATGATAT3 0 and TGGGTCATCTT CTCGCGGTT3 0 . Products were visualized following agarosegel electrophoresis.
